Key points are not available for this paper at this time.
When CODAC Behavioral Healthcare, the main provider of treatment services for corrections in Rhode Island, looks at its clientele with opioid use disorder (OUD), Vivitrol (depot naltrexone) is preferred by no one. The patients want either methadone or buprenorphine, CODAC CEO Linda Hurley explained in a webinar this month (for the first part of this two‐part article, see ADAW ( https://onlinelibrary.wiley.com/doi/10.1002/adaw.34254 ).
Alison Knopf (Fri,) studied this question.